Research Leaders Across New York State Form Empire State Cellular Therapy Consortium
To expand on early progress in the emerging field of cell and gene therapy, five research centers across New York State are collaborating to develop new cell therapies for cancer and other diseases.
Clinical Scorecard: Research Leaders Across New York State Form Empire State Cellular Therapy Consortium
At a Glance
Category Detail
Condition Cancer and neurological disorders Key Mechanisms Cell and gene therapies utilizing the body's immune system Target Population Patients with blood cancers, solid tumors, and noncancerous conditions Care Setting Academic research centers and clinical trials
Key Highlights
Collaboration among five leading research centers in New York State Focus on accelerating research and expanding access to innovative therapies 15 new cell and gene therapies approved by the FDA in the last two years Plans to broaden applications to solid tumors and nonmalignant diseases Inaugural symposium scheduled for February 2025 at Roswell Park Guideline-Based Recommendations
Diagnosis
Utilize advanced diagnostic tools to identify candidates for cell and gene therapies Management
Implement collaborative clinical trials to evaluate new therapies Monitoring & Follow-up
Regular follow-up and assessment of treatment efficacy and safety Risks
Consider potential adverse effects associated with cell and gene therapies Patient & Prescribing Data
Individuals with malignant and nonmalignant diseases
Innovative therapies showing promise for long-term remissions and cures
Clinical Best Practices
Encourage collaboration among research centers to enhance treatment options Leverage shared resources for efficient clinical trial execution Provide training opportunities for junior investigators and trainees References
